Literature DB >> 6795122

Group C Neisseria meningitidis variant polysaccharide vaccines in children.

M C Steinhoff, E B Lewin, E C Gotschlich, J B Robbins.   

Abstract

The currently United States-licensed group C Neisseria meningitidis vaccine, composed of the O-acetyl-positive capsular polysaccharide, is poorly immunogenic and does not afford protection from disease to infants and young children. Group C N. meningitidis O-acetyl-negative polysaccharide vaccine induces higher titers in adults than does the O-acetyl-positive vaccine. We compared the immunogenicity of these vaccines in 2-year-old children. Reactions were minimal and did not differ between the two vaccines. The postvaccination geometric mean titer was twofold greater in the O-acetyl-negative group (1.58 versus 0.73 micrograms of antibody per ml). The rates of decline in titer were similar in both groups. Further study regarding immunogenicity of and the anamnestic response to the O-acetyl-negative vaccine is warranted in the age group (less than 18 months) at highest risk for invasive meningococcal disease.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6795122      PMCID: PMC350834          DOI: 10.1128/iai.34.1.144-146.1981

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  9 in total

1.  Serologic response to serogroup C meningococcal vaccine in Brazilian preschool children.

Authors:  V Amato Neto; H Finger; E C Gotschlich; R A Feldman; C A de Avila; S R Konichi; W C Laus
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1974 May-Jun       Impact factor: 1.846

2.  Standardization and control of meningococcal vaccines, group A and group C polysaccharides.

Authors:  K H Wong; O Barrera; A Sutton; J May; D H Hochstein; J D Robbins; J B Robbins; P D Parkman; E B Seligmann
Journal:  J Biol Stand       Date:  1977

3.  Comparative immunogenicity of vaccines prepared from capsular polysaccharides of group C Neisseria meningitidis O-acetyl-positive and O-acetyl-negative variants and Escherichia coli K92 in adult volunteers.

Authors:  M P Glode; E B Lewin; A Sutton; C T Le; E C Gotschlich; J B Robbins
Journal:  J Infect Dis       Date:  1979-01       Impact factor: 5.226

4.  Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children.

Authors:  R Gold; M L Lepow; I Goldschneider; T F Draper; E C Gotshlich
Journal:  J Infect Dis       Date:  1979-11       Impact factor: 5.226

5.  Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70.

Authors:  R Gold; M S Artenstein
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

6.  Strucutres of the capsular polysaccharides of Neisseria meningitidis as determined by 13C-nuclear magnetic resonance spectroscopy.

Authors:  H J Jennings; A K Bhattacharjee; D R Bundle; C P Kenny; A Martin; I C Smith
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

7.  Immune Response of human infants of polysaccharide vaccines of group A and C Neisseria meningitidis.

Authors:  R Gold; M L Lepow; I Goldschneider; E C Gotschlich
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

8.  Quantitative determination of the human immune response to immunization with meningococcal vaccines.

Authors:  E C Gotschlich; M Rey; R Triau; K J Sparks
Journal:  J Clin Invest       Date:  1972-01       Impact factor: 14.808

9.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

  9 in total
  7 in total

1.  Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation.

Authors:  Peter C Fusco; Esmé K Farley; Chun-Hsien Huang; Samuel Moore; Francis Michon
Journal:  Clin Vaccine Immunol       Date:  2007-03-21

2.  Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains.

Authors:  P Richmond; R Borrow; J Findlow; S Martin; C Thornton; K Cartwright; E Miller
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 3.  Meningococcal vaccines. Current status and future possibilities.

Authors:  H Peltola
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

4.  Specificity of antibodies to O-acetyl-positive and O-acetyl-negative group C meningococcal polysaccharides in sera from vaccinees and carriers.

Authors:  G Arakere; C E Frasch
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

5.  Group B streptococcal conjugate vaccines elicit functional antibodies independent of strain O-acetylation.

Authors:  Pia S Pannaraj; Morven S Edwards; Kristen T Ewing; Amanda L Lewis; Marcia A Rench; Carol J Baker
Journal:  Vaccine       Date:  2009-05-31       Impact factor: 3.641

6.  Reactivity and immunogenicity of bivalent (AC) and tetravalent (ACW135Y) meningococcal vaccines containing O-acetyl-negative or O-acetyl-positive group C polysaccharide.

Authors:  I Vodopija; Z Baklaic; P Hauser; P Roelants; F E André; A Safary
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

7.  Discovery and characterization of sialic acid O-acetylation in group B Streptococcus.

Authors:  Amanda L Lewis; Victor Nizet; Ajit Varki
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-19       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.